CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.430
-0.250 (-9.33%)
At close: Oct 23, 2025, 4:00 PM EDT
2.310
-0.120 (-4.94%)
After-hours: Oct 23, 2025, 7:18 PM EDT
CytoMed Therapeutics Revenue
CytoMed Therapeutics had revenue of 450.69K SGD in the half year ending June 30, 2025, with 58.57% growth. This brings the company's revenue in the last twelve months to 729.88K, up 63.03% year-over-year. In the year 2024, CytoMed Therapeutics had annual revenue of 503.37K, down -0.86%.
Revenue (ttm)
729.88K SGD
Revenue Growth
+63.03%
P/S Ratio
53.96
Revenue / Employee
16,974 SGD
Employees
43
Market Cap
28.04M USD
Revenue Chart
* This company reports financials in SGD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 503.37K | -4.36K | -0.86% |
Dec 31, 2023 | 507.74K | 143.82K | 39.52% |
Dec 31, 2022 | 363.91K | 250.07K | 219.67% |
Dec 31, 2021 | 113.84K | 54.37K | 91.43% |
Dec 31, 2020 | 59.47K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GDTC News
- 21 days ago - CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 21 days ago - CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - GlobeNewsWire
- 2 months ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 3 months ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 6 months ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 9 months ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 10 months ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga